Don i agree with your assessment and would add this along with many others here. most on this board research alot of biotechs. i for one can not really find another biotech with aria marketcap with good results of phase 3 drug. a second drug that has steller results so far and has the potential to be blockbuster and we own 100 percent of it. and a 3rd drug ready to start testing.
so i ask other aria longs what would we put our money into. ARIA imho at this price or 7.32 still offers the best potential/risk biotech that i know of going forward over the next 1-2 years??
Don't forget to factor in a non-NA partnership(s) for Ponatinib. Because it will probably involve significant upfronts, it could have a very positive effect on the share price.
And MRK might have some more data coming out on the other trials of Rida in other cancer indications.
News 
Market Data 
Discover 
